- Patent Title: Histone deacetylase as a modulator of PDLI expression and activity
-
Application No.: US16000678Application Date: 2018-06-05
-
Publication No.: US10576066B2Publication Date: 2020-03-03
- Inventor: Alejandro V. Villagra , Eduardo M. Sotomayor
- Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
- Applicant Address: US FL Tampa
- Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Current Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Current Assignee Address: US FL Tampa
- Agency: Meunier Carlin & Curfman LLC
- Main IPC: A61K31/437
- IPC: A61K31/437 ; A61K45/06 ; A61K31/17 ; A61K31/416 ; A61K31/422 ; A61K31/505 ; A61K31/4045 ; A61K31/4406 ; A61K31/506
Abstract:
Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a therapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof.
Public/Granted literature
- US20190298701A9 HISTONE DEACETYLASE AS A MODULATOR OF PDLI EXPRESSION AND ACTIVITY Public/Granted day:2019-10-03
Information query
IPC分类:
